AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.

阿姆斯特丹--（商业新闻短讯）--VectorY Therapeutics是一家开发用于治疗神经退行性疾病的创新矢量化抗体疗法的生物技术公司，今天宣布任命行业资深人士Khurem Farooq为独立董事会成员，立即生效。

Khurem Farooq is an accomplished industry leader who brings more than 20 years of operational and drug development experience. He currently serves as the CEO at Aiolos Bio which recently announced an agreement to be acquired by GSK. Previously Khurem served as the CEO of Gyroscope, which was acquired by Novartis in 2021.

Khurem Farooq是一位有成就的行业领导者，拥有20多年的运营和药物开发经验。他目前担任Aiolos Bio的首席执行官，该公司最近宣布了一项由葛兰素史克收购的协议。此前，库雷姆担任陀螺仪的首席执行官，该公司于2021年被诺华收购。

Prior to Gyroscope, Khurem was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, part of the Roche Group, where he led the commercialization and launch planning of a number of medicines and contributed to the development of several pipeline products. Khurem holds a Master’s Degree in Business Administration as well as an Honours degree in Biological Sciences..

在加入陀螺仪之前，库雷姆是罗氏集团旗下基因泰克公司免疫学和眼科业务部门的高级副总裁，他领导了许多药物的商业化和启动计划，并为几种管道产品的开发做出了贡献。库雷姆拥有工商管理硕士学位和生物科学荣誉学位。。

The appointment follows VectorY’s $138m series A announced in November 2023, co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund II, to support clinical development of the company’s lead program in ALS, and preclinical development of pipeline programs based on VectorY’s broad technology platform..

这一任命是在2023年11月VectorY宣布由EQT生命科学和Forbion增长机会基金II共同领导的价值1.38亿美元的A系列之后做出的，以支持该公司ALS领先项目的临床开发，以及基于VectorY广泛技术平台的管道项目的临床前开发。。

Sander van Deventer, CEO of VectorY, commented: “We are delighted to welcome Khurem to VectorY as an independent board member. He brings a wealth of leadership experience across operations, strategy and drug development in the pharma and biotech industry, which will be invaluable as we move in the next stage of growth of our company and advance our lead program VTx-002 for the treatment of Amyotrophic Lateral Sclerosis (ALS) towards clinical development .”.

VectorY首席执行官Sander van Deventer，评论道：“我们很高兴欢迎Khurem成为VectorY的独立董事会成员。他在制药和生物技术行业的运营、战略和药物开发方面带来了丰富的领导经验，随着我们进入公司下一个发展阶段，推进治疗肌萎缩性侧索硬化症（ALS）的领先项目VTx-002，这将是非常宝贵的走向临床发展。”。

Khurem Farooq, Independent board member at VectorY, said: “I am excited to join this talented team at such a pivotal time. I am very impressed with VectorY’s unique capabilities to combine gene and antibody therapy drug development as well as its pipeline progress. The company’s innovative approach has the potential to overcome limitations of current therapies and translate into disease-modifying treatments across multiple neurodegenerative diseases, including ALS.”.

VectorY独立董事会成员Khurem Farooq，表示：“在如此关键的时刻，我很高兴能加入这个才华横溢的团队。VectorY将基因和抗体治疗药物开发及其管道进展相结合的独特能力给我留下了深刻印象。该公司的创新方法有可能克服当前疗法的局限性，并转化为多种神经退行性疾病的疾病缓解疗法es，包括ALS。”。

-Ends-

-结束-

Photograph available upon request

可根据要求提供照片

Notes to Editors

编辑注释

About VectorY

关于VectorY

VectorY is on a mission to provide patients with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease.

VectorY的使命是通过创建转化性矢量化抗体治疗，为神经退行性疾病患者提供更长，更好的生活。我们的平台将精确治疗性抗体的前景与一次性基于AAV的中枢神经系统递送相结合。抗体，AAV载体，蛋白质降解，制造和神经科学方面独特的内部专业知识推动了神经退行性疾病（如ALS和亨廷顿舞蹈病）急需的疾病缓解疗法的快速发展。

For more information, see www.vectorytx.com..

有关更多信息，请访问www.vectorytx.com。。

About VTx-002

关于VTx-002

VTx-002 is being developed to delay disease progression and preserve the quality of life of ALS patients. VTx-002, currently in preclinical development, is a vectorized antibody that selectively clears misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells. Thereby, it restores the essential function of TDP-43 in the nucleus leading to preservation of neuronal cell function and health.

正在开发VTx-002以延缓疾病进展并保持ALS患者的生活质量。目前处于临床前开发阶段的VTx-002是一种矢量化抗体，可选择性地从神经元细胞的细胞质中清除错误折叠和聚集的TDP-43。因此，它恢复了TDP-43在细胞核中的基本功能，从而保护了神经元细胞的功能和健康。

ALS is a devastating condition that in the Western world has an estimated lifetime risk of 1:250 in males and 1:400 in females. It is characterized by the progressive degeneration of motor neurons, which leads to an average life expectancy after diagnosis of only two to five years. Presently there is no cure available to stop or reverse ALS and currently available treatments only slow disease progression by months..

ALS是一种毁灭性疾病，在西方世界，男性的终生风险估计为1:250，女性为1:400。它的特征是运动神经元进行性退化，诊断后的平均预期寿命仅为2至5年。目前还没有治愈或逆转ALS的方法，目前可用的治疗方法只能将疾病进展减缓数月。。